This article is more than 5 years old. Information may no longer be current.

Rockwell Medical reports increase in sales, lower R&D expenses for 4th quarter of 2013

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Rockwell Medical Inc. reported that net income for the fourth quarter of 2013 grew 21% to $2.1 million, compared to the same quarter in 2012.  Sales increased 7.4% to $14 million. Research and development expenses fell 51% to 5.8 million, compared to $11.8 million in the fourth quarter of 2012.

Rockwell reported a loss of $8.3 million or $0.21 per share, a 39% reduction compared to $13.7 million or $0.66 per share in the fourth quarter of 2012.

(Study affirms safety profile of Rockwell's iron replacement drug for dialysis patients) 

"CitraPure now accounts for close to 70% of all Rockwell Dry Acid sales," Robert L. Chioini, Founder, Chairman and CEO of Rockwell said during an earnings call. "We expect CitraPure will soon become the new standard of care in dialysis. Going forward, we expect our sales momentum to continue."

For the year, Rockwell reported a loss of $48.8 million or $1.48 per share, a 9.7% reduction compared to $54 million or $2.65 per share in 2012.

"As you know we reported successful study results from our pivotal CRUISE-1 and CRUISE-2 trials in the second half of 2013," Chioini said about Treferic,Rockwell's investigational iron-replacement drug."Both pivotal Phase 3 studies met their primary efficacy end point and delivered exceptional safety results. We are on track to submit the NDA in the next few weeks. Once that occurs, we anticipate the FDA’s decision in approximately 12 months "Given our successful Phase 3 clinical results, demonstrating efficacy and safety, the benefit, the risk ratio for Triferic appears favorable and we expect FDA approval."